By Business/Source
Currency:USD
2026/Q2
Stock NameRevenueRatio
Development and commercialization of human therapeutics20.73M100.00%
By Country/Region
Currency:USD
2025/FY
Stock NameRevenueRatio
US74.96M69.76%
Europe32.5M30.24%